BCR and chronic myelogenous leukemia, BCR-ABL1 positive: A further important clinical question for taking forward such drug combinations, which these papers suggest are of major interest, is that we must define either appropriate clinical response criteria or a surrogate marker, such as reduction of BCR/ABL transcripts in CML.